Frazier Life Sciences Management, L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 2,416,952 shares of RYTM stock, worth $136 Million. This represents 6.82% of its overall portfolio holdings.
Number of Shares
2,416,952
Previous 2,371,304
1.93%
Holding current value
$136 Million
Previous $97.4 Million
30.05%
% of portfolio
6.82%
Previous 5.74%
Shares
7 transactions
Others Institutions Holding RYTM
# of Institutions
191Shares Held
67.3MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$405 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$378 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$359 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$341 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$218 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.13B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...